Clinical efficacy and evaluation of ritexitinib (Lefenox) in the treatment of vitiligo

Ritlecitinib (Ritlecitinib) is an oral small moleculeJAK3 selective inhibitor that blocks Janus< The /span>kinase-signal transducer and activator of transcription (JAK-STAT) pathway inhibits the self-attack response mediated by immune cells, thereby reducing melanocyte damage. This mechanism provides a new targeted treatment direction for autoimmune skin diseases such as vitiligo.

Clinical studies have shown that ritexitinib can effectively improve the color and extent of skin lesions in patients with vitiligo. Some patients with moderate to severe vitiligo have obvious pigment recovery in the white spots on their face and hands after oral treatment for several weeks to months. In the study, the efficacy was evaluated through the white spot area index (VASI) and response rate (Repigmentation Rate). Most patients experienced varying degrees of pigment recovery during 12 to 24 weeks of treatment.

The efficacy evaluation of ritexitinib is also reflected in its maintenance effect on chronic vitiligo. Compared with traditional topical glucocorticoids or calcineurin inhibitors, ritexitinib can systematically regulate the immune response and reduce the recurrence rate. For patients with multiple sites and poor response to local treatment, oral ritixitinib provides a feasible treatment option and improves patients' psychological burden and quality of life.

In terms of safety, clinical observations show that ritexitinib is well tolerated, and common adverse reactions are mild to moderate headache, upper respiratory tract infection, or slight changes in blood counts. Most side effects can be controlled through dose adjustment or symptomatic treatment. Overall, ritixitinib shows the advantages of rapid onset, sustained stability and controllable side effects in the treatment of vitiligo, providing new clinical hope for patients with moderate to severe and refractory vitiligo.

Reference link:https://www.drugs.com